Why is Onconova Therapeutics (ontx) stock trading higher today?
The Onconova Therapeutics Inc (NASDAQ: ONTX) stock increased by 12.35% today. This is why. The Onconova Therapeutics Inc (NASDAQ: ONTX) stock increased by 12.35% today. Investors are responding positively to a bullish research report.
What is Onconova Therapeutics'net margin and return on equity?
Mar 31, 2022 · Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 72.0% and is now trading at $1.51. View which stocks have been most impacted by COVID-19.
What are analysts'target prices for Onconova Therapeutics'stock?
Mar 18, 2021 · Onconova Therapeutics Inc. (ONTX) is going up in the pre-market on March 18, 2021, as of this writing. The stock went up 14.95% yesterday as well. Still, Onconova Therapeutics Inc. (ONTX) is going up in the pre-market on March 18, 2021, as of this writing. The stock went up 14.95% yesterday as well. Still, there is no latest development to support their gains.
Who is the new director of Corporate Development at Onconova?
May 21, 2021 · Onconova Therapeutics (ONTX) stock, which fell over 21 percent on May 20, was up over 1,400 percent on May 21. What happened to ONTX stock and why it is up sharply?
Will onconova stock go up?
On average, Wall Street analysts predict that ONCONOVA THERAPEUTICS's share price could reach $5.50 by Mar 1, 2023. The average ONCONOVA THERAPEUTICS stock price prediction forecasts a potential upside of 241.61% from the current ONTX share price of $1.61.
Is onconova Therapeutics a good buy?
Onconova Therapeutics has received a consensus rating of Buy.
Why is ONTX going up?
The increase was primarily related to costs related to special and annual general meeting expenses in the 2021 period. Ladenburg Thalmann analyst Ahu Demir initiates coverage on Onconova Therapeutics (NASDAQ:ONTX) with a Buy rating and announces Price Target of $7.
Is onconova a good stock?
Zacks' proprietary data indicates that Onconova Therapeutics, Inc. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ONTX shares relative to the market in the next few months.
Is ONTX getting delisted?
Odonate Therapeutics (NASDAQ:ODT) plummets 39% premarket as it expects the trading of its common stock on Nasdaq to be suspended at the opening of business on Jan. 18, 2022.Jan 7, 2022
Is Onconova Therapeutics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are curren...
How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World He...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 171,900 sha...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for On...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($...
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 202...
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 12 month target prices for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Steven M. Fruchtman , President, Chief Executive Officer & Director ( Link...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Annexon (ANNX) , scPharmaceuticals (SCPH) , BriaCell Therapeutics (BCTX) , Nex...
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
How much will Onconova Therapeutics lose in 2021?
Earlier this week, Onconova Therapeutics released its earnings for the first quarter of 2021 and posted a net loss of $4.7 million compared to a net loss of $5.1 million in the same period in 2020. The company’s R&D expense fell from $3.4 million to $1.9 million over the period.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company that's discovering and developing novel products for cancer patients. It isn't unusual for clinical-stage companies to see massive volatility around the release of trial results or news of drug approval.
What is reverse split on ONTX?
After the split, the total number of outstanding shares of ONTX will fall from around 236.714 million shares to only about 15.781 million. A reverse split is the opposite of a stock split where the company splits its shares to increase the liquidity. In 2020, both Apple and Tesla split their ...
When does a company reverse its stock split?
In contrast, a company does a reverse stock split when its stock falls too low and it faces the risk of delisting. According to the NYSE listing rules, a stock is subject to delisting if the average price in any 30 consecutive trading day is below $1. Article continues below advertisement.
What happens after a stock split?
After the stock split, the stock falls in conjunction with the split ratio. So, a stock that has been split 2-for-1 would fall by around half on the day it trades after the split completion.
How many shares of Onconova Therapeutics have changed hands?
As of this writing, more than 245 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is about 39 million shares. Onconova Therapeutics is a biopharmaceutical company with a focus on developing new treatments for cancer.
Where is Onconova Therapeutics located?
It operates out of its headquarters in Pennsylvania.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
When is Onconova 2021?
(NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021 . The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are
How much was the General and Administrative expenses in 2021?
General and administrative expenses were $2.2 million for the first quarter of 2021, compared with $1.8 million for the first quarter of 2020. The increase was primarily related to higher special stockholder meeting by proxy expenses and insurance costs in the 2021 period.
How much is research and development in 2021?
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020. The decrease was primarily related to lower expenses for the oral rigosertib combination program and the completed Phase 3 INSPIRE study in the 2021 period.
Is Onconova a multi-kinase inhibitor?
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China. Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, ...
